News

NDTV Profit on MSN10h
Birlasoft Gets Antique Stock Broking's 'Hold' Initiation As Gradual Turnaround Seen — Check Target Price
Antique Stock Broking has initiated coverage on Birlasoft, an IT services provider, with a 'hold' rating and a target price of Rs 450, suggesting a potential upside of 4% on the counter. The brokerage ...
ABP News on MSN2h
Cross-Border Payment DeGays Cost Indian Businesses Millions: Zil Money's Technology Delivers Payments In Minutes
Zil Money's blockchain-powered platform enables Indian businesses to receive US payments in minutes instead of 5-7 days, ...
The Manila Times1h
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
Werewolf Therapeutics, Inc. (the 'Company” or 'Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...
NSE-SME Stock Launches QIP, Sets Floor Price At Rs 268.85 Per Share
One of the leading creative visual effects (VFX) companies in the industry, Phantom Digital Effects Limited (NSE: PHANTOMFX), ...
Mongabay News on MSN20h
U.S. federal agency clears ways for deep-sea mining — and companies are lining up
This story was supported by the Pulitzer Center’s Ocean Reporting Network, where Elizabeth Claire Alberts is a fellow. On ...
Longeveron Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)
Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trialPhase 2 clinical trial initiation anticipated in first half of 2026Pediatric ca ...
Nomura predicts 18% downside in Godrej Properties, sees Phoenix Mills falling 11% on lofty valuations
Nomura initiates 'reduce' ratings on Godrej Properties and Phoenix Mills. The brokerage projects an 18% downside for Godrej ...
Solid Biosciences Inc.: Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic ...
SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies - - SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Design ...
Solid Biosciences Announces FDA IND And Health Canada CTA Approval For First-In-Class Cardiac Gene Therapy To Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies - - SGT-501 has rec ...
Santé log23h
Jade Biosciences to Participate in Two Upcoming Investor Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies ...